soul trial oral semaglutide cardiovascular outcomes 2025 results (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Semaglutide cardiovascular outcomes align more

The key implication here is that FOXO4-DRI has the potential to develop supportive care protocols to reduce long-term adverse effects of chemotherapy and improve overall quality of life for cancer survivors

Safety and efficacy of the SNAP 12-hour acetylcysteine regimen for the treatment of paracetamol overdose

GLP1 medications are moving rapidly from niche treatment to mainstream force, with implications that stretch far beyond weight loss alone

Metabolic signaling refers to the messages cells use to manage energy use and storagefor example, how cells decide when to use glucose, store fuel, or shift energy production pathways in response to changing conditions in an experimental model

Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1)

Los Angeles has no shortage of wellness providers, but not all NAD services are delivered with the same level of clinical professionalism, scheduling flexibility, and patient support